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Background. C-reactive protein (CRP), an acute phase reactant and marker of inflammation, has been shown to predict risk of
incident cardiovascular events. However, few studies have comprehensively examined six common single-nucleotide
polymorphisms (SNPs) in the CRP gene, haplotypes, and plasma CRP levels with risk of coronary heart disease (CHD). Methods
and Findings. We conducted parallel nested case-control studies within two ongoing, prospective cohort studies of U.S.
women (Nurses’ Health Study) and men (Health Professionals Follow-up Study). Blood samples were available in a subset of
32,826 women and 18,225 men for biomarker and DNA analyses. During 8 and 6 years of follow-up, 249 women and 266 men
developed incident nonfatal myocardial infarction or fatal CHD, and controls (498 women, 531 men) were matched 2:1 on age,
smoking, and date of blood draw from participants free of cardiovascular disease at the time the case was diagnosed. Among
both women and men, minor alleles were significantly associated with higher CRP levels for SNPs 1919A.T and 4741G.C, but
associated with lower CRP levels for SNPs 2667G.C and 3872C.T. SNP 2667G.C was individually associated with increased
risk of CHD in both women [OR 1.57 (95% CI 1.01–2.44); p=0.047] and men [1.93 (95% CI 1.30–2.88); p=0.001]. Two of the five
common haplotypes were associated with lower CRP levels, and Haplotype 4 which included minor alleles for 2667 and 3872
was associated with significantly lower CRP levels and an elevated risk of CHD. The remaining SNPs or haplotypes were not
associated with CHD in both populations. Conclusions. Common variation in the CRP gene was significantly associated with
plasma CRP levels; however, the association between common SNPs and CRP levels did not correspond to a predicted change
in CHD risk. The underlying inflammatory processes which predict coronary events cannot be captured solely by variation in
the CRP gene.
Citation: Pai JK, Mukamal KJ, Rexrode KM, Rimm EB (2008) C-Reactive Protein (CRP) Gene Polymorphisms, CRP Levels, and Risk of Incident Coronary
Heart Disease in Two Nested Case-Control Studies. PLoS ONE 3(1): e1395. doi:10.1371/journal.pone.0001395
INTRODUCTION
Inflammatory processes are involved in the initiation and
progression of atherosclerotic lesions, as well as in the development
of atheroma complications,[1] and markers of inflammation may
reflect subclinical vascular inflammation and be useful diagnostic
tools.[2] C-reactive protein (CRP), an acute phase reactant, is a
marker of inflammation, and has been shown to independently
predict risk of future cardiovascular events among initially healthy
men and women.[3–6] However, since CRP levels can be
influenced by age, smoking, body mass index, and other clinical
or environmental risk factors,[7–9] it remains to be determined
whether CRP acts causally in atherogenesis, in addition to serving
as a reliable marker of future events.[10]
Recent family studies suggest heritability estimates of CRP
ranging from 27–40%,[11,12] and it is hypothesized that genetic
variation in the CRP gene may influence plasma CRP levels and
subsequent risk of CHD. Several studies have reported individual
single nucleotide polymorphisms (SNPs) to be associated with CRP
levels,[13–21] and of these, Zee et al.,[15] which included SNP
2667G.C, Casas et al.,[19] which included SNP 3014G.A, also
examined associations with cardiovascular events. Both studies
reported no association with the individual SNPs and risk of
cardiovascular disease.
To date, few studies of both men and women have simultaneously
examined common genetic variation in the CRP gene, haplotypes,
plasma CRP levels, and risk of incident cardiovascular events. In the
Rotterdam Study, the common haplotypes associated with higher
CRP levels were not associated with risk of coronary heart
disease.[22] Similarly, among men in the Physicians’ Health Study,
none of the common SNPs associated with higher CRP levels were
associated with an increased risk of atherothrombotic events,
whereas one SNP not associated with CRP was associated with a
decreased risk of myocardial infarction.[23] Alternatively, in the
Cardiovascular Health Study among elderly adults, haplotypes were
significantly associated with CRP levels, and stroke and cardiovas-
cular mortality, but not associated with myocardial infarction.[24]
Because these studies included some, but not all of the same SNPs,
estimated haplotypes are not directly comparable, and thus,
summary conclusions cannot be made. Utilizing the existing
sequencing data and available haplotype-tagging SNPs, we set out
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PLoS ONE | www.plosone.org 1 January 2008 | Issue 1 | e1395to comprehensively examine common variation in the CRP gene
with plasma CRP levels and risk of incident coronary heart disease
among two independent populations of middle-aged men and
women.
METHODS
Study Population
The Nurses’ Health Study (NHS) and the Health Professionals
Follow-up Study (HPFS) are prospective cohort investigations
among 121,700 female U.S. registered nurses aged 30–55 years at
baseline in 1976 (NHS) and 51,529 U.S. male health professionals,
aged 40–75 years at baseline in 1986 (HPFS). Information about
health and disease is assessed biennially and information about
diet every four years by self-administered questionnaires.[25,26]
Between 1989 and 1990, a blood sample was requested from all
participants of the NHS, and returned from 32,826 women.
Similarly, between 1993 and 1995, a blood sample was returned
from 18,225 men in the HPFS. Participants who provided blood
samples were similar in terms of cardiovascular risk factors to those
who did not, albeit somewhat younger. In the NHS, among
women without cardiovascular disease or cancer prior to blood
draw, we identified 249 women with incident nonfatal myocardial
infarction (MI) or fatal coronary heart disease (CHD) over 8 years
of follow-up. In the HPFS, we similarly identified 266 men with
incident nonfatal MI or fatal CHD over 6 years of follow-up.
Using risk-set sampling which selects controls from the base
population that gave rise to the cases,[27] controls were randomly
selected 2:1 matched on age, smoking, date of blood draw, and
fasting status (women only) from participants free of cardiovascular
disease at the time the case was diagnosed.
The study protocol was approved by the Institutional Review
Board of the Brigham and Women’s Hospital and the Harvard
Schoolof PublicHealthHuman Subjects Committee Review Board.
Assessment of coronary heart disease
Myocardial infarction was confirmed by study physicians blinded to
participant’s exposure status if it met the World Health Organiza-
tion’s criteria (symptoms plus either diagnostic electrocardiographic
changes or elevated levels of cardiac enzymes).[28,29] Deaths were
identified from state vital records and the National Death Index or
reported by the participant’s next of kin or the postal system. Fatal
coronary heart disease was confirmed by hospital records or on
autopsy, or if coronary heart disease was listed as the cause of death
on the death certificate, if it was the underlying and most plausible
cause, and if evidence of previous coronary heart disease was
available. Among women, 80.3% of the cases were nonfatal MI, and
19.7% were fatal CHD. Among men, 73.7% of the cases were
nonfatal MI, and 26.3% were fatal CHD.
Measurement of biochemical variables
Blood samples were collected in sodium heparin tubes for women
and liquid EDTA for men, placed on ice packs, stored in
Styrofoam containers, returned to our laboratory via overnight
courier, and centrifuged and aliquoted for storage in liquid
nitrogen freezers (2130uC or colder). Inflammatory marker levels
were largely unaffected by transport conditions and reproducible
within persons over time.[30,31]
Plasma biomarkers were measured for nonfatal MI and fatal
CHD cases and their controls. C-reactive protein concentrations
were determined using an immunoturbidimetric high sensitivity
assay using reagents and calibrators from Denka Seiken (Niigata,
Japan) with assay day-to-day variability between 1 and 2%. This
assay has a sensitivity of 0.1 mg/L, and the day-to-day variability
of the assay at concentrations of 0.91, 3.07, and 13.38 mg/L were
2.8, 1.6, and 1.1%, respectively. The intra-assay coefficients of
variation were ,10% for both HPFS and NHS. Total, HDL, and
directly assessed LDL cholesterol, and triglycerides were measured
using standard methods with reagents from Roche Diagnostics
(Indianapolis, IN) and Genzyme (Cambridge, MA). Study samples
were sent to the laboratory for analysis in randomly ordered
batches, and the laboratory was blinded to case-control status.
SNP selection and genotyping
Tocomprehensivelyassessthe geneticvariation inthe CRPgene,we
utilized a multi-stage approach. (1.) First, Carlson et al.[32] had
resequenced the CRP gene in 23 unrelated European-descent
individuals (EA) in the Utah/Centre d’Etude du Polymorphisme
Humain (CEPH) panel (Coriell Institute for Medical Research,
Camden,NJ),andusinglinkagedisequilibriumhadselectedtagSNPs
that summarized the common variation in the CRP gene. The five
tagSNPs polymorphic in EAs, included a triallelic 1440C.T.A
(rs3091244) and a commonly studied rare 2667G.C. (2.)
Additionally, we conducted a comprehensive search of SNPs
available in dbSNP (as of August 2005) which were polymorphic
in Caucasians and had a minor allele frequency .1%, and resulted
in two additional SNPs with low minor allele frequency (MAF)
[4362G.Ca n d5 6 0 6 G .T]. (3.) Finally, the International HapMap
Project[33] showed that two tagSNPs [1919A.T and 3872C.T]
were sufficient to assess the variation in the gene, and these two were
already included in the selected SNPs. The triallelic SNP could not
be genotyped using Taqman; however, previous LD analyses[9]
showed that SNPs 3872C.Ta n d5 2 3 7 A .G together serve as a
proxy so these two SNPs were used instead.
DNA was extracted from the buffy coat fraction of centrifuged
blood using the QIAmp Blood Kit (Qiagen, Chatsworth, CA). The
primary genotyping technique was Taqman SNP allelic discrimina-
tion by means of an ABI 7900HT (Applied Biosystems, Foster City,
CA) and the primers and probes used were designed by Applied
Biosystems: 1919A.T (rs1417938), 2667G.C (rs1800947),
3014G.A (rs1130864), 3872C.T (rs1205), 4362A.T
(rs3093080), 4741G.C (rs3093068), 5237A.G (rs2808630), and
5606G.T (rs3093071). Replicate quality control samples were
included and genotyped with 100% concordance. Cases were not
perfectly matched to controls because a few subjects could not be
genotyped with this platform, but genotype call rates did not differ
between cases and controls. We initially genotyped the NHS, and
then conducted a replication study in the HPFS. Among NHS, the
minor allele frequencies for 4362A.T (0.6% cases, 1.1% controls)
and 5606G.T (1%cases,0.5%controls) wereverylow; thus,wedid
notfurthergenotypethemintheHPFS.Theremaining6SNPswere
selected for final analyses.
Statistical analyses
All analyses were conducted separately for men and women. For
baseline characteristics, we used ANOVA methods to compare
least square means adjusted for matching factors, and the Chi-
square and/or Fisher’s Exact tests to compare proportions
between cases and controls, between genotype and allele
frequencies, and to assess Hardy-Weinberg equilibrium. The
primary genetic model was additive (genotype as a continuous
variable). Conditional and unconditional logistic regression
adjusting for matching factors and multivariate covariates were
used to estimate the relative risk (RR) and results were similar.
With risk-set sampling, the odds ratio derived from the logistic
regression directly estimates the hazard ratio, and thus, the relative
risk.[27] In our multivariable model we further adjusted for
CRP SNPs and CHD
PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1395alcohol intake (nondrinker, 0.1 to 4.9 g/d, 5.0 to 14.9 g/d, 15.0 to
29.9 g/d, $30.0 g/d), body mass index (,25, 25 to 29.9, $30 kg/
m
2),physicalactivity(quintiles), nonsteroidal anti-inflammatorydrug
(NSAID) use (yes/no), parental history of CHD before the age of 60
(yes/no), history of diabetes (yes/no) and hypertension (yes/no) at
baseline, total:HDL-cholesterol ratio (quintiles), and hormone
therapy among women (never, past, current). Baseline was defined
as the year of blood draw. Lewontin’s D prime (D’) and the
correlation coefficient (r
2) were calculated as two measures of linkage
disequilibrium (LD) between CRP polymorphisms among control
participants. CRP levels were not normally distributed and were log-
transformed for analyses. Multivariable linear regression analyses
were conducted to model the association between CRP SNPs and
CRP levels among control participants.
Using an expectation-maximization algorithm in SAS Genetics,
we estimated frequencies for the five most common (.5%
frequency) haplotypes in each population and imputed subject-
specific expected haplotypes.[34,35] Haplotype-specific odds ratios
based on the additive model were calculated using unconditional
logistic regression adjusting for matching factors with the most
frequent haplotype set as the reference. The likelihood ratio test was
used to calculate the global p-value comparing the model with
haplotypes to the model without haplotypes. We present otherwise
uncorrected p-values, and emphasize the 95% confidence intervals
around risk estimates from two independent populations.
All p-values presented are two-tailed and p-values below 0.05
were considered statistically significant. All analyses were per-
formed using SAS version 9 (SAS Institute, Cary, NC).
RESULTS
Baseline characteristics
Cardiovascular risk factors were higher or more frequent among
the cases compared to the controls in both men and women
(Table 1), and for most of the CRP genotype frequencies, there
were no statistical differences by case and control status (Table 2).
The 2667C allele was significantly more frequent among cases than
controls in women (p=0.05) and men (0.006), and the 5237G allele
was more frequent among cases then controls in women only
(p=0.004). The observed allele frequencies for all SNPs, except for
5237A.G among women (p=0.03) and 4741G.C among men
(p=0.001), were within Hardy-Weinberg equilibrium among the
controls. The pairwise LD measures and correlation coefficients
between CRP polymorphisms were analyzed among the control
women and men (Table 3). The minor alleles for 1919A.T and
3014G.A were in high pairwise LD (r
2.0.95), whereas
2667G.C, 3872C.T, 4741G.C, and 5237A.G were not in
high LD (r
2,0.30).
CRP SNPs, plasma CRP levels, and risk of coronary
heart disease
Under the additive model, 2667G.C was associated with an
increased risk of CHD in both women (RR 1.57, 95% confidence
interval [CI] 1.01–2.44) and men (RR 1.93, 95% CI 1.30–2.88);
however, none of the other SNPs were associated with risk of
CHD in both men and women (Table 4). Multivariable
adjustment did not change these results. Furthermore, among
the controls, individual SNPs were associated with plasma CRP
levels, with similar associations and directions for both women and
men (Table 4). Under the same model, SNPs 2667G.C and
3872C.T were associated with 22–37% lower CRP levels,
whereas 4741G.C was associated with ,40% higher CRP levels.
SNPs 1919A.T and 3014G.A were associated with approxi-
mately 20% higher CRP levels, whereas 5237A.G was not
associated with CRP levels in either men or women.
CRP haplotypes, plasma CRP levels, and risk of
coronary heart disease
Five common haplotypes (H1-H5) had an estimated frequency
$5% (Table 5). H1 with minor alleles of 1919A.T and
3014G.A and major alleles of all others, was the most frequent
haplotype and set as the reference haplotype in subsequent
analyses. H2, with minor allele of 5237A.G, and H3, with minor
allele of 3872C.T, had estimated frequencies ranging from 25–
Table 1. Baseline characteristics of participants with incident CHD (cases) and matched
* controls among women (Nurses’ Health
Study) and men (Health Professionals Follow-up Study)
{
..................................................................................................................................................
Women Men
Characteristics Cases Controls P
{ Cases Controls P
{
N 249 498 266 531
Age (years) 60.3 6 0.09 60.3 6 0.06 0.93 65.2 6 0.13 65.1 6 0.09 0.93
Current Smokers (%) 32.1 31.9 - 12.7 12.7 -
Caucasian
1 (%) 96.1 96.5 0.83 98.1 98.4 .0.99
Postmenopausal (%) 90.3 87.8 0.32 - - -
Body mass index (kg/m
2) 26.9 6 0.31 25.4 6 0.22 ,0.001 26.2 6 0.21 25.7 6 0.15 0.05
History of hypertension (%) 57.4 29.3 ,0.001 42.1 30.9 0.002
History of diabetes (%) 19.7 6.6 ,0.001 9.4 4.5 0.007
Parental history of CHD before age 60 (%) 27.7 12.3 ,0.001 15.0 10.9 0.10
Total:HDL-cholesterol ratio 4.88 6 0.09 4.05 6 0.06 ,0.001 5.37 6 0.09 4.75 6 0.06 ,0.001
CRP (mg/L) 3.08 (2.67, 3.55) 2.16 (1.95, 2.39) ,0.001 1.58 (1.38, 1.80) 1.17 (1.07, 1.29) ,0.001
*Matched on age, smoking status, date of blood drawing, and fasting status (women only)
{Values are least square mean 6 standard error for continuous variables and proportions for categorical variables, except for CRP, which is shown as log-transformed
geometric mean and 95% confidence interval
{P for difference between cases and controls by matching factor-adjusted t-Test for rows with means, and by Chi-Square Test for rows with proportions
1Race unknown in 10 cases and 21 controls (HPFS); 18 cases and 16 controls (NHS)
doi:10.1371/journal.pone.0001395.t001
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PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e139530%. Neither H2 nor H3 was associated with risk of CHD.
However, H4, with an estimated frequency of 6–7%, was
associated with an increased risk of CHD in both women (RR
1.66, 95% CI 1.02–2.71) and men (RR 1.90, 95% CI 1.25–2.88).
The difference between H3 and H4 may be attributable to the
minor allele of 2667G.C.
Where individual SNPs were associated with CRP levels,
estimated haplotypes were associated with plasma CRP levels in a
similar manner. The tagging SNPs for H1 were individually
associated with higher CRP levels. Compared to H1, H3 and H4
were associated with 24–44% lower CRP levels among both men
and women, and these findings were as expected from their
individual variant alleles. For comparison, H1 and H5, which
included the triallelic proxy, were both associated with higher
CRP levels.
Overall, the global p-value comparing the model with
haplotypes to the model without was not statistically significant
among women (p=0.37) but significant among men (p=0.04).
DISCUSSION
In two independent populations of predominantly Caucasian men
and women, we related common variation in the CRP gene and
estimated common haplotypes with plasma CRP levels and risk of
incident CHD. CRP SNPs and associated haplotypes were
strongly associated with plasma CRP levels. However, neither
Table 2. Genotype frequency for CRP polymorphisms among cases and controls in Nurses’ Health Study (Women) and Health
Professionals Follow-up Study (Men)
..................................................................................................................................................
Women Men
Cases Controls p-value
* Cases Controls p-value
*
1919A.T rs1417938
AA 122 (51.7) 231 (49.6) 122 (50.0) 234 (48.1)
AT 93 (39.4) 185 (39.7) 98 (40.2) 201 (41.3)
TT 21 (8.9) 50 (10.7) 0.72 24 (9.8) 52 (10.7) 0.87
Total 236 466 244 487
2667G.C rs1800947
GG 205 (85.1) 433 (89.8) 209 (81.0) 458 (89.3)
GC 35 (14.5) 49 (10.2) 45 (17.4) 51 (9.9)
CC 1 (0.41) 0 (0.0) 0.05 4 (1.6) 4 (0.8) 0.006
Total 241 482 258 513
3014G.A rs1130864
GG 125 (52.7) 238 (51.0) 126 (50.8) 235 (47.8)
GA 94 (39.7) 178 (38.1) 98 (39.5) 205 (41.7)
AA 18 (7.6) 51 (10.9) 0.39 24 (9.7) 52 (10.6) 0.73
Total 237 467 248 492
3872C.T rs1205
CC 107 (44.4) 210 (44.2) 111 (43.7) 237 (46.7)
CT 108 (44.8) 225 (47.4) 113 (44.5) 222 (43.7)
TT 26 (10.8) 40 (8.4) 0.54 30 (11.8) 49 (9.6) 0.57
Total 241 475 254 508
4741G.C rs3093068
GG 206 (86.6) 419 (89.2) 233 (90.0) 435 (86.5)
GC 32 (13.5) 48 (10.2) 25 (9.6) 60 (11.9)
CC 0 (0.0) 3 (0.64) 0.22 1 (0.4) 8 (1.6) 0.22
Total 238 470 259 503
5237A.G rs2808630
AA 126 (52.3) 216 (45.4) 124 (51.0) 256 (51.3)
AG 85 (35.3) 224 (47.1) 96 (39.5) 204 (40.9)
GG 30 (12.5) 36 (7.6) 0.004 23 (9.5) 39 (7.8) 0.74
Total 241 476 243 499
*P, chi-square, or Fisher’s exact test for cells less than 20.
doi:10.1371/journal.pone.0001395.t002
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CRP SNPs and CHD
PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1395the individual SNPs nor common haplotypes were associated with
risk of CHD in the direction that would be predicted by their
association with CRP levels.
Inflammation is thought to contribute to increased cardiovas-
cular risk, and C-reactive protein, an important component of the
innate immune system, is the most extensively studied marker of
inflammation.[3–6] Many studies have reported individual single
nucleotide polymorphisms (SNPs) to be significantly associated
with baseline CRP levels (Table 6).[9,13–21,23,24,36,37]
Though some of the individual SNP results have been conflicting,
our results are consistent with the majority of published findings.
On the other hand, the studies that assessed common variation
and haplotypes in the CRP gene with plasma CRP levels differed
in SNP selection methodology and estimated haplotypes.[9,16,22–
24,32,37] For example, Carlson et al.[32] resequenced 47 samples
from panels with African American and European descent
individuals to select seven tagging SNPs for eight haplotypes in
the CARDIA study. On the other hand, Miller et al.[23]
resequenced 192 individuals in the Women’s Health Study with
extreme discordant baseline CRP levels and selected seven tagging
SNPs for six common haplotypes among Caucasians participants
in three sub-cohorts. In the Rotterdam Study, Kardys et al.
genotyped 3 tagging SNPs (3014, 3872, and 4741) selected from
SeattleSNPs which were sufficient to infer four common
haplotypes.[22] Though overall haplotypes were not exactly
replicated, the more recent studies shared much overlap in
selected SNPs. Based on LD patterns and similar reference groups,
our results were similar to what has been previously reported. The
haplotypes associated with lower CRP levels were similar, as were
the haplotypes associated with higher CRP levels.
Several studies have shown H4 as associated with significantly
lower CRP levels.[9,16,23,24,32] However, specifically of impor-
tance, few studies have assessed haplotypes, and H4 in particular,
with risk of incident CHD. Thus far, the results have been unclear
and conflicting. Though the Rotterdam Study did not genotype
2667G.C, they reported four haplotypes significantly associated
with CRP levels, and reported no associations with CHD.[22] A
recent study in the Cardiovascular Health Study of older adults
reported no association between five CRP haplotypes and risk of
MI among white participants, and the relative risk of MI for our
Table 3. Pairwise linkage disequilibrium (D’) and correlation coefficients (r
2) between CRP polymorphisms and control women and
men
..................................................................................................................................................
Women Linkage Disequilibrium (D’)
Polymorphism 1919 2667 3014 3872 4741 5237
Correlation Coefficient (r
2) 1919 - 1.000 0.9838 0.9823 1.000 1.000
2667 0.0235 - 1.000 0.9553 1.000 0.7563
3014 0.9526 0.0237 - 0.9822 1.000 0.9611
3872 0.2003 0.1034 0.2027 - 1.000 1.000
4741 0.0278 0.0034 0.0260 0.0305 - 1.000
5237 0.1945 0.0134 0.1729 0.2152 0.0269 -
Men Polymorphism 1919 2667 3014 3872 4741 5237
Correlation Coefficient (r
2) 1919 - 1.000 0.9950 0.9835 1.000 1.000
2667 0.0273 - 1.000 0.9680 1.000 1.000
3014 0.9900 0.0270 - 0.9517 0.8431 1.000
3872 0.1988 0.1260 0.1912 - 0.7588 1.000
4741 0.0362 0.0050 0.1038 0.0209 - 1.000
5237 0.1845 0.0242 0.1820 0.1822 0.0335 -
doi:10.1371/journal.pone.0001395.t003
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Table 4. Association of CRP SNPs with risk of coronary heart disease, and with plasma CRP levels among women and men
..................................................................................................................................................
Women Men
Cases/
Controls
Odds ratio
(95% CI)
* p-value
Multiplicative
change in CRP
levels
{ p-value
{
Cases/
Controls
Odds ratio
(95% CI)
* p-value
Multiplicative
change in CRP
levels
{ p-value
{
1919A.T 236/466 0.90 (0.70–1.14) 0.37 1.22 0.009 244/487 0.93 (0.73–1.18) 0.55 1.18 0.02
2667G.C 241/482 1.57 (1.01–2.44) 0.047 0.63 0.01 258/513 1.93 (1.30–2.88) 0.001 0.72 0.01
3014G.A 237/467 0.88 (0.69–1.12) 0.28 1.15 0.08 248/492 0.89 (0.70–1.13) 0.32 1.22 0.006
3872C.T 241/475 1.08 (0.85–1.37) 0.54 0.76 0.001 254/508 1.17 (0.92–1.48) 0.88 0.78 0.001
4741G.C 238/470 1.22 (0.76–1.94) 0.42 1.38 0.006 259/503 0.70 (0.44–1.09) 0.12 1.41 0.01
5237A.G 241/476 0.93 (0.72–1.19) 0.56 0.98 0.86 243/499 1.07 (0.84–1.37) 0.59 0.96 0.56
*Conditional logistic regression under the additive genetic model
{Matching factor-adjusted, log-transformed, multiplicative change per copy of the allele among controls
{P for change in CRP levels
doi:10.1371/journal.pone.0001395.t004
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PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e1395H4 equivalent was 0.93 (95% CI 0.72–1.21).[24] On the other
hand, though H4 was not associated with CRP levels in the
Physicians’ Health Study, 3872C.T individually was associated
with lower CRP levels, and with an increased risk of MI (odds
ratio: 1.29, 95% CI 0.99–1.67).[23] Furthermore, the odds ratio
for 2667G.C was suggestive of a 50% increase as well, but the
confidence interval was much wider. Taken together, these results
suggest that 2667G.C and 3872C.T, though associated with
lower CRP levels, may be associated with an elevated risk of CHD.
A number of SNPs in the promoter region of the CRP gene
have been shown to affect changes in transcription factor binding
and gene promoter activity.[17,32] The triallelic SNP has been
associated with increased promoter activity and higher CRP
levels,[32] and haplotypes of the promoter triallelic and rs3093032
SNPs affect transcription factor binding, transcriptional activity,
and CRP levels.[17] The major alleles of 3872C.T and
5237A.G together serve as a proxy for the triallelic,[9] and the
2-SNP haplotype was associated with higher CRP levels in our
studies as well as in others.[9,23,32] Otherwise, more functionality
data are needed for CRP SNPs.
There is emerging consistency in the literature that polymor-
phisms in the CRP gene are associated with plasma CRP levels,
Table 5. Common CRP haplotypes, risk of CHD, and relative effects of haplotypes on plasma CRP levels
..................................................................................................................................................
CRP SNP 1919 2667 3014 3872 4741 5237
Multiplicative change in CRP
per copy relative to H1 among
controls
{
Women A.TG .CG .AC .TG .CA .G Freq (%) OR (95%CI)
{ p-value p-value
Haplotype #:
H 1 1010002 9 . 1 1 . 0 - R e f -
H 2 0000013 0 . 7 1 . 0 1 ( 0 . 7 7 – 1 . 3 4 ) 0 . 9 3 0 . 8 8 0 . 1 4
H 3 0001002 6 . 4 0 . 9 9 ( 0 . 7 4 – 1 . 3 4 ) 0 . 9 7 0 . 7 6 0 . 0 0 6
H 4 0101005 . 8 1 . 6 6 ( 1 . 0 2 – 2 . 7 1 ) 0 . 0 4 0 . 5 6 0 . 0 0 2
H 5 0000106 . 0 1 . 2 7 ( 0 . 7 9 – 2 . 0 4 ) 0 . 3 2 1 . 1 9 0 . 1 5
H6
1 ------,5.0 0.93 (0.39–2.24) 0.88 0.68 0.26
p-value
¥ 0.37
CRP SNP 1919 2667 3014 3872 4741 5237 Multiplicative change in CRP
per copy relative to H1 among
controls
{
Men A.TG .CG .AC .TG .CA .G Freq (%) OR (95%CI)
{ p-value
Haplotype #:
H 1 1010003 0 . 8 1 . 0 - R e f -
H 2 0000012 8 . 7 1 . 1 1 ( 0 . 8 4 – 1 . 4 7 ) 0 . 4 5 0 . 8 6 0 . 0 6
H 3 0001002 4 . 8 1 . 0 3 ( 0 . 7 7 – 1 . 3 7 ) 0 . 8 7 0 . 7 6 0 . 0 0 4
H 4 0101007 . 1 1 . 9 0 ( 1 . 2 5 – 2 . 8 8 ) 0 . 0 0 3 0 . 6 4 0 . 0 0 2
H 5 0000106 . 7 0 . 8 2 ( 0 . 5 2 – 1 . 3 0 ) 0 . 4 0 1 . 1 9 0 . 2 7
H6
1 ------,5.0 1.04 (0.45–2.39) 0.93 0.97 0.89
p-value
¥ 0.04
*Cutoff set as $5.0%, based on 744 women and 781 men.
{Haplotype-specific ORs (multiplicative increase in odds per copy of haplotype) using unconditional logistic regression, adjusted for matching factors
{Log-transformed CRP adjusted for matching factors
1All other haplotypes
¥Globally-adjusted likelihood ratio test
doi:10.1371/journal.pone.0001395.t005
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Table 6. Brief summary of literature examining single CRP SNPs with CRP levels, and CHD where available
..................................................................................................................................................
Association with CRP levels Association with CHD
q levels Q levels no association q risk Q risk no association
1919A.T [14,20] [23,36]
2667G.C [21] [14–16,20,23] [13,18] [15]
3014G.A [13,16,19,20,22] [18] [19,22]
3872C.T [16,20,22,23] [22]
4741G.C [22,23,37] [22]
5237A.G
* [18,20,21,23] [23]
*SNP 5237 was in high LD with another commonly reported SNP -717A.G (rs2794521).
doi:10.1371/journal.pone.0001395.t006
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PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1395but whether there is also an association between polymorphisms
and risk of coronary events remains unclear. While CRP
polymorphisms are strongly associated with plasma levels, these
polymorphisms contribute only 1.4–5.0% of the phenotypic
variation, a level comparable to (or less than) that from
environmental and lifestyle factors.[9,23] In addition to environ-
mental stimuli, CRP is induced by other inflammatory cytokines,
and additional genes in the inflammatory pathway may regulate
CRP levels as well. Thus, our results are consistent with CRP as a
good indicator of the inflammatory state and as a risk marker.
However, the apparent influence in baseline CRP levels due to
CRP polymorphisms may not be large enough to alter CHD risk,
which may explain the lack of association between the majority of
common haplotypes in the CRP gene and risk of CHD in either
the NHS or the HPFS. The remaining exception would be
haplotype 4, and it is possible that CRP is an epiphenomenon of
vascular inflammation and not directly involved in vascular
pathobiology, or possibly protective. Alternatively, the CRP
polymorphisms and haplotypes may be in LD with pro-
atherogenic variants in nearby gene regions which would not be
captured in this study.
Several potential limitations should be discussed regarding the
current two studies. In genetic association studies, population
stratification is often a concern. However, population stratification
should be minimized in the NHS and HPFS because both cohorts
are predominantly Caucasian, and similar results were observed
when restricted to Caucasians only. Additionally, we recognize
that the relative socioeconomic homogeneity of the cohorts does
not represent random samples of U.S. men and women and may
not be generalizeable to other populations. Though the homoge-
neity is unlikely to influence genetic predisposition, it may be a
strength in reducing residual confounding from unmeasured
factors related to socioeconomic status. Also, the distribution of
cardiovascular risk factors such as smoking status and history of
diabetes were different between the men and women, and may
have mediated influences through CRP. Finally, chance may be
an explanation for the statistically significant findings. Neverthe-
less, we included a replication study by examining both the NHS
and HPFS, and the overall results were identical between the two
independent populations.
Our study provides a comprehensive assessment of the common
genetic variation in the CRP gene with plasma CRP levels and risk
of incident CHD among two independent populations. Among
predominantly Caucasian men and women, CRP genotypes and
haplotypes were consistently and significantly associated with
plasma CRP levels. However, the relationship between genotype
and CRP levels did not translate largely to an associated change in
CHD risk, and Haplotype 4 in particular may be important in
predicting other clinical events. These data suggest that the
underlying inflammatory processes which predict coronary events
cannot be captured solely by variation in the CRP gene, and other
regulatory genes should be examined.
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